Nordmark Biotech

Executive Summary

Nordmark Biotech, operating as Nordmark Pharma GmbH, is a German full-service partner with over a century of experience in developing and manufacturing biopharmaceutical active ingredients and finished drug products. The company has established itself as a global leader in niche biologics, particularly pancreatin and collagenase, which are critical for treating pancreatic insufficiency and wound healing, respectively. Nordmark offers an integrated 'one-stop-shop' value chain covering development, analytics, regulatory support, and commercial manufacturing. Its long-standing expertise and reputation for high-quality products have made it a preferred partner for pharmaceutical companies worldwide. With a proven track record and a focus on complex biologics, Nordmark is well-positioned to capitalize on growing demand for specialty enzymes and biologics. The company's private status allows it to invest in long-term growth initiatives, such as capacity expansions and new product development. While facing competition from larger contract development and manufacturing organizations (CDMOs), Nordmark's niche specialization and century-long history provide a durable competitive advantage. Its outlook remains positive, supported by steady demand for its core products and potential expansions into new therapeutic areas.

Upcoming Catalysts (preview)

• Q3 2026Completion of pancreatin manufacturing capacity expansion at Uetersen site85% success
• Q4 2026FDA approval for new collagenase-based wound care product60% success
• H1 2027Strategic partnership with a large pharma for novel biologic delivery45% success